Theriva Biologics, Inc. (TOVX)Healthcare | Biotechnology | Rockville, United States | NYSE American
0.23 USD
-0.01
(-3.266%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 0.23 -0.01 (-0.006%) ⇩ (July 13, 2026, 7:58 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 5:16 a.m. EDT
The immediate outlook is clouded by severe technical weakness and a lack of liquidity. Despite recent headlines regarding clinical trial progress, the stock is trading significantly below its 50-day moving average, indicating persistent selling pressure. Volume has collapsed to a fraction of its average, suggesting a lack of institutional interest or capital inflow to drive a recovery. While the statistical forecast model hints at a negligible upward lean, its low confidence score confirms that price action remains erratic and driven by noise rather than a clear trend. From a long-term perspective, the investment case is fundamentally broken. The company has endured a catastrophic multi-year decline, losing nearly 100% of its value over the last nine years. The most recent annual performance was another sharp drop, extending a streak of four consecutive years of negative returns. This trajectory is not a temporary correction; it reflects a structural deterioration where the market has repeatedly reassessed the business quality downward. With negative earnings, massive losses, and no revenue growth to speak of, the company lacks the financial engine required for a sustained comeback. The price-to-book ratio appears attractive only because the book value itself is eroding alongside the share price. Finally, there is no dividend component to consider. The company is burning through cash reserves to fund operations and research, resulting in zero payouts to shareholders. Investors seeking income will find nothing here. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.215914 |
| AutoETS | 0.218713 |
| MSTL | 0.230834 |
| AutoTheta | 0.479693 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 30% |
| H-stat | 7.28 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.299 |
| Excess Kurtosis | -0.78 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 23.982 |
| Revenue per Share | 0.014 |
| Market Cap | 10,738,884 |
| Forward P/E | -1.17 |
| Beta | 1.10 |
| Previous Name | Synthetic Biologics, Inc. |
| Website | https://therivabio.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.52 |
| Address1 | 9,605 Medical Center Drive |
| Address2 | Suite 270 |
| All Time High | 262,500.0 |
| All Time Low | 0.16 |
| Ask | 0.0 |
| Ask Size | 3,500 |
| Average Daily Volume10 Day | 4,521,320 |
| Average Daily Volume3 Month | 21,206,804 |
| Average Volume | 21,206,804 |
| Average Volume10Days | 4,521,320 |
| Beta | 1.095 |
| Bid | 0.0 |
| Bid Size | 5,000 |
| Book Value | 0.336 |
| City | Rockville |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.234 |
| Current Ratio | 1.633 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 0.2389 |
| Day Low | 0.2251 |
| Debt To Equity | 23.982 |
| Display Name | Theriva Biologics |
| Dividend Date | 1,534,118,400 |
| Earnings Call Timestamp End | 1,711,369,800 |
| Earnings Call Timestamp Start | 1,711,369,800 |
| Earnings Timestamp End | 1,755,174,600 |
| Earnings Timestamp Start | 1,755,174,600 |
| Ebitda | -12,624,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.0 |
| Enterprise To Revenue | 0.003 |
| Enterprise Value | 884 |
| Eps Current Year | -0.2 |
| Eps Forward | -0.2 |
| Eps Trailing Twelve Months | -0.56 |
| Esg Populated | 0 |
| Exchange | ASE |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 0.2894 |
| Fifty Day Average Change | -0.055400014 |
| Fifty Day Average Change Percent | -0.19143058 |
| Fifty Two Week Change Percent | -52.0 |
| Fifty Two Week High | 0.86 |
| Fifty Two Week High Change | -0.62600005 |
| Fifty Two Week High Change Percent | -0.727907 |
| Fifty Two Week Low | 0.16 |
| Fifty Two Week Low Change | 0.074 |
| Fifty Two Week Low Change Percent | 0.4625 |
| Fifty Two Week Range | 0.16 - 0.86 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,166,452,200,000 |
| Float Shares | 45,143,241 |
| Forward Eps | -0.2 |
| Forward P E | -1.17 |
| Free Cashflow | -4,870,250 |
| Full Exchange Name | NYSE American |
| Full Time Employees | 15 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 1.0 |
| Gross Profits | 300,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01633 |
| Held Percent Institutions | 0.043169998 |
| Implied Shares Outstanding | 45,892,668 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ir Website | http://www.syntheticbiologics.com/investors |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,724,630,400 |
| Last Split Factor | 1:25 |
| Long Business Summary | Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma. The company also develops VCN-11 for treating solid tumors; SYN-004 (ribaxamase), an oral capsule prophylactic therapy that is in Phase 1b/2a clinical trials for the prevention of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT); and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) for multiple gastrointestinal and metabolic indications. In addition, it develops clinical stage products, such as SYN-006 to prevent aGVH, clostridioides difficile infection, and microbiome damage in patients treated with carbapenem antibiotics; and SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics. The company has a license agreement with Rasayana Therapeutics, Inc. to research, develop, manufacture, and commercialize any product that includes SYN-020, as well as a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland. |
| Long Name | Theriva Biologics, Inc. |
| Market | us_market |
| Market Cap | 10,738,884 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_24424557 |
| Most Recent Quarter | 1,774,915,200 |
| Name Change Date | 2,026-07-13 |
| Net Income To Common | -22,969,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 11,101,436 |
| Number Of Analyst Opinions | 2 |
| Open | 0.231 |
| Operating Cashflow | -14,369,000 |
| Operating Margins | -7.09 |
| Payout Ratio | 0.0 |
| Phone | 301 417 4364 |
| Post Market Change | -0.0059999973 |
| Post Market Change Percent | -2.5641015 |
| Post Market Price | 0.228 |
| Post Market Time | 1,783,987,105 |
| Prev Name | Synthetic Biologics, Inc. |
| Previous Close | 0.2419 |
| Price Eps Current Year | -1.17 |
| Price Hint | 4 |
| Price To Book | 0.6964286 |
| Price To Sales Trailing12 Months | 35.79628 |
| Profit Margins | 0.0 |
| Quick Ratio | 1.58 |
| Quote Source Name | Delayed Quote |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.0079 |
| Regular Market Change Percent | -3.26581 |
| Regular Market Day High | 0.2389 |
| Regular Market Day Low | 0.2251 |
| Regular Market Day Range | 0.2251 - 0.2389 |
| Regular Market Open | 0.231 |
| Regular Market Previous Close | 0.2419 |
| Regular Market Price | 0.234 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 467,204 |
| Return On Assets | -0.22600001 |
| Return On Equity | -1.38911 |
| Revenue Per Share | 0.014 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 45,892,668 |
| Shares Percent Shares Out | 0.0317 |
| Shares Short | 1,452,613 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 2,723,844 |
| Short Name | Theriva Biologics, Inc. |
| Short Percent Of Float | 0.0317 |
| Short Ratio | 0.09 |
| Source Interval | 15 |
| State | MD |
| Symbol | TOVX |
| Target High Price | 4.0 |
| Target Low Price | 1.0 |
| Target Mean Price | 2.5 |
| Target Median Price | 2.5 |
| Total Cash | 14,431,000 |
| Total Cash Per Share | 0.314 |
| Total Debt | 3,693,000 |
| Total Revenue | 300,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.56 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 0.2673 |
| Two Hundred Day Average Change | -0.033300012 |
| Two Hundred Day Average Change Percent | -0.12457917 |
| Type Disp | Equity |
| Volume | 467,204 |
| Website | https://therivabio.com |
| Zip | 20,850 |